Skip to content
Review

Neuroimaging in the era of biologically defined Alzheimer's disease and disease-modifying therapy.

Oct 2026 · Lancet Neurology · Vol 25 10, pp. 939-951 · 2 citations · 143 references
Medicine

TL;DR

Neuroimaging is now a cornerstone of Alzheimer's disease care and a crucial discriminator tool for characterising brain injury across the lifespan and with emerging fluid biomarkers, neuroimaging supports accurate diagnosis, prognosis, and treatment monitoring.

Abstract

Disease-modifying therapies and biomarker-based diagnostic frameworks will fundamentally altered the clinical diagnosis and management of Alzheimer's disease. Diagnosis is increasingly anchored in the biological evidence of pathology rather than clinical presentation alone, with implications for treatment eligibility, prognosis, and monitoring. In clinical practice, patients with memory complaints can present with complex mixed pathologies that develop across the lifespan. Brain imaging, particularly MRI and PET, plays a crucial role in visualising these cumulative abnormalities. With Alzheimer's disease-specific therapies now available in many regions of the world, amyloid PET plays a central role in establishing Alzheimer's disease diagnosis, determining eligibility for amyloid-targeting therapies, and quantifying treatment-related amyloid clearance. In settings where available, tau PET informs biological stage, prognosis, and clinical heterogeneity. MRI remains indispensable for differential diagnosis, the assessment of comorbid and vascular pathology, and monitoring for complications, particularly amyloid-related imaging abnormalities. Technological advances-including quantitative imaging, artificial intelligence, accelerated acquisition, and workflow optimisation-are improving reliability, efficiency, and access to these tools. Neuroimaging is now a cornerstone of Alzheimer's disease care and a crucial discriminator tool for characterising brain injury across the lifespan. With emerging fluid biomarkers, neuroimaging supports accurate diagnosis, prognosis, and treatment monitoring.

View source

Similar papers

Review Open access Sep 2026

Understanding Alzheimer's disease through biomarkers: pathology, progression, and clinical application.

Alzheimer's disease (AD) is a progressive neurodegenerative disorder and the leading cause of dementia worldwide accounting for an estimated 60% to 80% of cases. Biomarkers play an integral role in AD randomized clinical trials (RCTs), providing objective measures of disease pathology, progression, and therapeutic effi...

Xiao-Lan Zhang, Michael F. Murphy, Henry J. Riordan et al. · 0 citations
Review Oct 2026

Clinical pathways for cognitively unimpaired individuals with Alzheimer's disease neuropathological change.

If anti-amyloid therapies prove beneficial for cognitively unimpaired people with ADNC and become part of routine practice, several key knowledge gaps must be addressed to support safe, scalable, real-world implementation of Alzheimer's disease treatment.

J. Graff-Radford, Leah Karliner, Deborah E. Barnes et al. · 1 citation
Review Open access Sep 2026

The complexities of diagnosing young-onset Alzheimer’s dementia and the need for swift identification

YOAD remains underrecognized and diagnostically challenging, limiting timely access to targeted therapies and the integration of multimodal biomarkers and genetic testing is essential for early diagnosis, as is the need for a comprehensive neuropsychological assessment to capture atypical phenotypes.

A. Schild, C. Bartels, R. Dodel · 0 citations

Innovative Technologies in Social

Despite remaining challenges, including safety concerns and the risk of amyloid-related imaging abnormalities, anti-amyloid therapies represent a major advancement in the treatment of Alzheimer's disease and mark a transition toward disease -modifying strategies.

Kacper Jaskulski, Julia Aleksandra Leśniak, Natalia Maria Leśniak et al. · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.